![An important step in improving the diagnostic challenges in AVP-D – Histiocytosis Association](https://oncodaily.com/pub/uploads/2024/01/1696277383326-e1704481208582.png)
An important step in improving the diagnostic challenges in AVP-D – Histiocytosis Association
Histiocytosis Association recently posted on LinkedIn:
“We recently learned of a new article on copeptin-based diagnostic tests (Hypertonic Saline vs. Arginine), published in the New England Journal of Medicine by Julie Refardt, M.D., Ph.D., and Cihan Atila, M.D., Ph.D. of Basal University in Switzerland.
This study and its findings present an important step in improving the diagnostic challenges in AVP-D (central diabetes insipidus). 10% of patients with AVP-D (DI) are diagnosed with histiocytosis. LCH, ECD, and RDD are the diagnoses that are seen with AVP-D (DI).
We were thrilled to spend a few minutes with Cihan Atila, M.D., Ph.D. to learn more about the study findings and its importance to improving the diagnosis of AVP-D (DI).
View our talk with him”
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023